Products
Faralimomab Biosimilar Monoclonal Antibody (IFN-α) for Research
Anti-IFNA1 therapeutic antibody (Pre-made Faralimomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Faralimomab is a mouse monoclonal antibody and an immunomodulator.[1][2]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-849-1mg | 1mg | 3090 |
| GMP-Bios-INN-849-10mg | 10mg | |
| GMP-Bios-INN-849-100mg | 100mg | |
| GMP-Bios-INN-849-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Faralimomab Biosimilar, Whole Mab, Anti-Ifna1 Antibody: Anti-IFL/IFN/IFN-ALPHA/IFN-alphaD/IFNA13/leIF D therapeutic antibody |
| INN Name | Faralimomab |
| Target | IFNA1 |
| Format | Whole mAb |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - nd |
| VD LC | IgG1 - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Medarex (Princeton NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - IFNA1
1. Protein Interferon alpha-1/13
2. Gene IFNA1
3. Organism Homo sapiens (Human)
Function
Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.
Miscellaneous
Interferons alpha-1 and alpha-13 have identical protein sequences.
